Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA1 | P02708 | 6/20 | 0.58 |
| ▸ | CHRNG | P07510 | 6/20 | 0.58 |
| ▸ | CHRNB1 | P11230 | 6/20 | 0.58 |
| ▸ | CHRND | Q07001 | 6/20 | 0.58 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.54 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.54 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.54 |
| ▸ | GRIA1 | P42261 | 5/20 | 0.53 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.49 |
| ▸ | CTSK | P43235 | 2/20 | 0.49 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | CTSH | P09668 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | CTSC | P53634 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9090677 | 1.00 | CHRNA1 (0.58) | CHRNA1CHRNGCHRNB1CHRNDCHRNB2 | |
| SCHEMBL9091432 | 1.00 | CHRNA1 (0.58) | CHRNA1CHRNGCHRNB1CHRNDCHRNB2 | |
| SCHEMBL7208901 | 0.99 | CHRND (0.60) | CHRNA1CHRNGCHRNB1CHRNDCHRNB2 | |
| SCHEMBL9089190 | 0.92 | CAPN1 (0.49) | CHRNA1CHRNGCHRNB1CHRNDCHRNB2 | |
| SCHEMBL9089141 | 0.91 | CHRND (0.61) | CHRNA1CHRNGCHRNB1CHRNDCHRNB2 | |
| SCHEMBL10632510 | 0.90 | CHRNA1 (0.48) | CHRNA1CHRNGCHRNB1CHRNDCHRNB2 | |
| SCHEMBL14345716 | 0.88 | CHRNB2 (0.67) | CHRNA1CHRNGCHRNB1CHRNDCHRNB2 | |
| SCHEMBL9088720 | 0.87 | CAPN1 (0.53) | CHRNA1CHRNGCHRNB1CHRNDCHRNB2 | |
| SCHEMBL9090745 | 0.86 | CHRNA1 (0.46) | CHRNA1CHRNGCHRNB1CHRNDCAPN1 | |
| SCHEMBL31607684 | 0.86 | CAPN1 (0.68) | CHRNA1CHRNGCHRNB1CHRNDCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-8104683-A | — | — | None | — | — | JP | disclosed |
| JP-7070098-A | — | — | None | — | — | JP | disclosed |
| US-20120003229-A1 | MODULATORS OF CYTOKINE MEDIATED SIGNALLING PATHWAYS AND INTEGRIN ALPHAVBETA3 RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY | GENESTE HERVE (DE) | 2012-01-05 | — | — | US | disclosed |
| EP-1239877-B1 | COMPOSITION COMPRISING A TNF-ALPHA INHIBITOR AND AN INTEGRIN ALPHAVBETA3 RECEPTOR ANTAGONIST | ABBOTT GMBH & CO KG (DE) | 2008-01-09 | — | — | EP | disclosed |
| US-20060159678-A1 | Modulators of cytokine mediated signaling pathways and integrin alphabeta3 receptor antagonists for combination therapy | GENESTE HERVE | 2006-07-20 | — | — | US | disclosed |
| US-5556853-A | THIOL PROTEASE INHIBITORS, TREATMENT OF OSTEOPOROSIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-09-17 | — | — | US | disclosed |
| JP-H08104683-A | EPOXY SUCCINIC ACID DERIVATIVE | TAKEDA CHEM IND LTD | 1996-04-23 | — | — | JP | disclosed |
| EP-0655447-A1 | Epoxysuccinic acid derivatives | Takeda Chemical Industries, Ltd. (JP) | 1995-05-31 | — | — | EP | disclosed |
| JP-H0770098-A | PHYSIOLOGICALLY ACTIVE PEPTIDE-BASED COMPOUND | SAGAMI CHEM RES CENTER | 1995-03-14 | — | — | JP | disclosed |
| JP-H00770098-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060159678-A1 | Modulators of cytokine mediated signaling pathways and integrin alphabeta3 receptor antagonists for combination therapy | ITGB3, IL6ST, IL1RN | CHRNA1 168/4885CHRNG 71/4885CHRNB1 192/4885 |
| US-20120003229-A1 | MODULATORS OF CYTOKINE MEDIATED SIGNALLING PATHWAYS AND INTEGRIN ALPHAVBETA3 RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY | ITGB3, ITGAV, ITGB1 | CHRNA1 172/4885CHRNG 66/4885CHRNB1 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.